Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 2, 2003, Pages 197-205

  Sørensen, Ulrik S ^a   Bleisch, Thomas J ^a   Kingston, Anne E ^a   Wright, Rebecca A ^a   Johnson, Bryan G ^a   Schoepp, Darryle D ^a   Ornstein, Paul L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMINO ACID; AMINO ACID RECEPTOR BLOCKING AGENT; BENZENE DERIVATIVE; DRUG DERIVATIVE; GLYCINE; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; RECOMBINANT PROTEIN; TRITIUM; XANTHENE DERIVATIVE; GLYCINE DERIVATIVE; METABOTROPIC RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE;

ARTICLE; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; METABOLISM; MOLECULAR CLONING; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN CELL; RACEMIC MIXTURE; RECEPTOR AFFINITY;

AMINO ACIDS; BENZENE DERIVATIVES; CELL LINE; CLONING, MOLECULAR; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; RECEPTORS, METABOTROPIC GLUTAMATE; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRITIUM; XANTHENES;

EID: 0037449352     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00387-5     Document Type: Article

References (39)

1. McBain C.J., Mayer M.L. Physiol. Rev. 74:1994;723.
2. Kyle, D. J.; Patch, R. J.; Karbon, E. W.; Ferkany, J. W. In Excitatory Amino Acid Receptors: Design of Agonists and Antagonists, Krogsgaard-Larsen, P.; Hansen, J. J., Eds.; Ellis Horwood: Chichester, 1992; pp 121-161.
3. Lees G.J. Drugs. 59:2000;33.
4. Bleakman D., Lodge D. Neuropharmacology. 37:1998;1187.
5. Fletcher E.J., Lodge D. Pharmacol. Ther. 70:1996;65.
6. Borges K., Dingledine R. Progr. Brain Res. 116:1998;153.
7. Chittajallu R., Braithwaite S.P., Clarke V.R.J., Henley J.M. Trends Pharmacol. Sci. 20:1999;26.
8. Shinozaki H. Excitatory Amino Acid Receptors: Design of Agonists and Antagonists. Krogsgaard-Larsen P., Hansen J.J. 1992;261-291 Ellis Horwood, Chichester.
9. Schoepp D.D. J. Pharmacol. Exp. Ther. 299:2001;12.
10. Ozawa S., Kamiya H., Tsuzuki K. Progr. Neurobiol. 54:1998;581.
11. Schoepp D.D., Conn P.J. Trends Pharmacol. Sci. 14:1993;13.
12. Bräuner-Osborne H., Egebjerg J., Nielsen E. Ø., Madsen U., Krogsgaard-Larsen P. J. Med. Chem. 43:2000;2609.
13. Parsons C.G., Danysz W., Quack G. Drug News Perspect. 11:1998;523.
14. Bruno V., Battaglia G., Copani A., D'Onofrio M., Iorio P.D., Blasi A.D., Melchiorri D., Flor P.J., Nicoletti F. J. Cereb. Blood Flow Metab. 21:2001;1013.
15. Monn J.A., Schoepp D.D. Annu. Rep. Med. Chem. 35:2000;1.
16. Schoepp D.D., Jane D.E., Monn J.A. Neuropharmacology. 38:1999;1431.
17. Pin J.-P., De Colle C., Bessis A.-S., Acher F. Eur. J. Pharmacol. 375:1999;277.
18. Hayashi Y., Tanabe Y., Aramori I., Masu M., Shimamoto K., Ohfune Y., Nakanishi S. Br. J. Pharmacol. 107:1992;539.
19. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Nakanishi S. J. Neurosci. 13:1993;1372.
20. Palmer E., Monaghan D.T., Cotman C.W. Eur. J. Pharmacol. 166:1989;585.
21. Schoepp D.D., Monn J.A., Marek G.J., Aghajanian G., Moghaddam B. CNS Drug Rev. 5:1999;1.
22. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., Schoepp D.D. Eur. J. Pharmacol. 377:1999;155.
23. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Mayne N.G., Wu S., Cockerham S.L., Burnett J.P., Belegaje R., Bleakman D., Monn J.A. Neuropharmacology. 36:1997;1.
24. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. J. Med. Chem. 40:1997;528.
25. Battaglia G., Monn J.A., Schoepp D.D. Neurosci. Lett. 229:1997;161.
26. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L. Jr., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. J. Med. Chem. 42:1999;1027.
27. Jane D.E., Jones P.L., St J., Pook P.C.-K., Tse H-W., Watkins J.C. Br. J. Pharmacol. 112:1994;809.
28. Ornstein P.L., Bleisch T.J., Arnold M.B., Wright R.A., Johnson B.G., Schoepp D.D. J. Med. Chem. 41:1998;346.
29. Ornstein P.L., Bleisch T.J., Arnold M.B., Kennedy J.H., Wright R.A., Johnson B.G., Tizzano J.P., Helton D.R., Kallman M.J., Schoepp D.D. J. Med. Chem. 41:1998;358.
30. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., Schoepp D.D. Neuropharmacology. 37:1998;1.
31. Ornstein P.L., Arnold M.B., Bleisch T.J., Wright R.A., Wheeler W.J., Schoepp D.D. Bioorg. Med. Chem. Lett. 8:1998;1919.
32. Johnson B.G., Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., Schoepp D.D. Neuropharmacology. 38:1999;1519.
33. Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., Schoepp D.D. J. Pharmacol. Exp. Ther. 298:2001;453.
34. Collado I., Ezquerra J., Mazón A., Pedregal C., Yruretagoyena B., Kingston A.E., Tomlinson R., Wright R.A., Johnson B.G., Schoepp D.D. Bioorg. Med. Chem. Lett. 8:1998;2849.
35. Maryanoff B.E., Reitz A.B. Chem. Rev. 89:1989;863.
36. Tamaru Y., Ochiai H., Sanda F., Yoshida Z.-i. Tetrahedron Lett. 26:1985;5529.
37. Beletskaya I.P., Cheprakov A.V. Chem. Rev. 100:2000;3009.
38. Cacchi S., Arcadi A. J. Org. Chem. 48:1983;4236.
39. Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., Schoepp D.D. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;546.